Group 1: Company Overview and Order Situation - The company has seen a significant increase in net new orders, amounting to RMB 101.6 million, representing a year-on-year growth of 20.7% [2] - The average price of new orders stabilized in 2025, with expectations for growth in 2026 [2] Group 2: Revenue Performance - Revenue from clinical trial technical services in 2025 reached RMB 32.67 billion, showing a slight increase of 2.79% year-on-year [3] - Revenue from clinical trial-related and laboratory services was RMB 34.47 billion, reflecting a year-on-year growth of 4.57% [4] Group 3: Profit Margins - The gross margin for the company's main business decreased from 33.27% in the previous year to 26.53% in 2025 [5] - The gross margin for clinical trial technical services dropped from 29.56% to 20.09%, primarily due to order cancellations and declining order prices [5] Group 4: Strategic Outlook and AI Integration - The company's core strategy focuses on advancing digitalization and intelligence, with a self-developed AI model platform now in commercial use [6] - AI is expected to significantly enhance efficiency in data management and medical writing, although it may lead to slight price reductions [6] - The company maintains a competitive advantage in core clinical trial processes due to high barriers in medical and compliance areas [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [7] Core Insights - The company reported a revenue of 6.833 billion yuan for 2025, representing a year-on-year growth of 3.48%, while the net profit attributable to the parent company was 888 million yuan, a significant increase of 119.15% [4][7] - The clinical trial technical services business showed signs of recovery, with a revenue of 3.267 billion yuan in 2025, up 2.79% year-on-year, despite a decline in domestic innovative drug clinical operations due to industry cycles [7] - New order prices have stabilized, and net new orders returned to rapid growth, amounting to 10.16 billion yuan in 2025, a year-on-year increase of 20.7% [7] Financial Data and Profit Forecast - Total revenue projections for the company are as follows: 2026E at 7.754 billion yuan, 2027E at 9.109 billion yuan, and 2028E at 11.154 billion yuan, with corresponding year-on-year growth rates of 13.5%, 17.5%, and 22.5% respectively [6] - The net profit attributable to the parent company is forecasted to be 1.177 billion yuan in 2026E, 1.382 billion yuan in 2027E, and 1.735 billion yuan in 2028E, with growth rates of 32.6%, 17.4%, and 25.5% respectively [6] - The company's projected PE ratios are 39 for 2026, 34 for 2027, and 27 for 2028, indicating a favorable valuation compared to peers [7]

Group 1 - The revenue from the clinical trial technical services segment reached 3.267 billion yuan, an increase from 3.178 billion yuan in the same period last year [1] - The revenue from clinical trial-related services and laboratory services increased by 4.1% year-on-year, from 3.425 billion yuan to 3.566 billion yuan [1] Group 2 - The company, Tigermed, reported an operating revenue of 6.833 billion yuan for the year ending December 31, 2025, representing a year-on-year increase of 3.48% [2] - The net profit attributable to the listed company was 888 million yuan, showing a significant increase of 119.15% year-on-year [2] - Basic earnings per share were reported at 1.04 yuan, with a proposed cash dividend of 1.26 yuan for every 10 shares to all shareholders [2]

Investment Rating - The report maintains a "Recommended" rating for the company [5]. Core Insights - The company achieved a revenue of 6.83 billion yuan in 2025, representing a year-on-year growth of 3.5%. The net profit attributable to shareholders reached 0.89 billion yuan, with a significant year-on-year increase of 119.2%. However, the net profit excluding non-recurring items decreased by 58.5% to 0.36 billion yuan [2][3]. - The company is experiencing a recovery in domestic demand and an increase in overseas orders, leading to a positive trend in revenue and profit. The total new orders reached 10.16 billion yuan, up 20.7% year-on-year, and the amount of contracts to be executed was 18.2 billion yuan, an increase of 15.3% [2][3]. - The clinical trial technical services business stabilized, with revenue of 3.27 billion yuan, a 2.8% increase. The SMO business saw growth driven by overseas orders, with ongoing SMO projects increasing from 2,253 to 2,753 [3]. Summary by Relevant Sections Financial Performance - In 2025, the company reported total revenue of 6.83 billion yuan, with a growth rate of 3.5%. The net profit attributable to shareholders was 0.89 billion yuan, reflecting a growth rate of 119.2% [4][10]. - The projected financial performance for 2026 to 2028 includes revenues of 7.62 billion yuan, 8.61 billion yuan, and 9.83 billion yuan, with corresponding net profits of 1.19 billion yuan, 1.58 billion yuan, and 2.04 billion yuan [4][10]. Business Segments - The clinical trial technical services segment generated 3.27 billion yuan in revenue, while the clinical trial-related services and laboratory services segment achieved 3.45 billion yuan, marking a 4.6% increase [3]. - The SMO business benefited from strong demand for cross-border orders, contributing to the overall growth of the company [3]. Future Outlook - The company is expected to continue its recovery, with projections indicating a gradual improvement in domestic innovative drug clinical operations by 2026 [3]. - The anticipated earnings per share (EPS) for 2026, 2027, and 2028 are 1.38 yuan, 1.83 yuan, and 2.37 yuan, respectively, with corresponding price-to-earnings (PE) ratios of 39, 29, and 23 times [4][10].

Core Viewpoint - Tiger Medical (03347) reported a revenue of 6.833 billion yuan for the year ending December 31, 2025, representing a year-on-year increase of 3.48% [1] Financial Performance - The net profit attributable to shareholders reached 888 million yuan, marking a significant year-on-year increase of 119.15% [1] - Basic earnings per share were reported at 1.04 yuan, with a proposed cash dividend of 1.26 yuan for every 10 shares to all shareholders [1] Segment Performance - Revenue from the clinical trial technology services segment was 3.267 billion yuan, up from 3.178 billion yuan in the same period last year [1] - Revenue from clinical trial-related services and laboratory services increased by 4.1% year-on-year, rising from 3.425 billion yuan to 3.566 billion yuan [1]

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I-IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Two funds under Yuanxin Yongfeng have heavily invested in Tiger Med, holding a total of 293,400 shares. Based on the previous closing price of 50.78 CNY, the current stock price of 53.32 CNY results in a daily floating profit of 745,200 CNY, with a total floating profit of 950,600 CNY over the past three days [2][8]. - Yuanxin Yongfeng Multi-Strategy Fund (004148) holds 185,900 shares, representing 3.18% of the fund's net value, while Yuanxin Yongfeng Consumption Upgrade Fund (004934) holds 107,500 shares, accounting for 3.3% of the fund's net value [3][7].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment and a cumulative increase of 6.82% over three consecutive days [1][4]. Company Overview - Tiger Med, officially known as Hangzhou Tiger Medical Technology Co., Ltd., was established on December 15, 2004, and went public on August 17, 2012. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the company is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - Longxin Fund has a significant holding in Tiger Med, with its Longxin Xianrui Mixed A Fund (519937) holding 50,000 shares, representing 0.71% of the fund's net value, making it the seventh-largest holding [2][5]. - The fund has realized a floating profit of approximately 127,000 CNY today, with a total floating profit of 162,000 CNY during the three-day increase [2][5]. - The Longxin Xianrui Mixed A Fund was established on June 2, 2016, with a current size of 16.30 million CNY. Year-to-date returns are 1.52%, with a one-year return of 5.08% and a cumulative return of 43.7% since inception [2][5]. Fund Manager Performance - The fund manager, Ye Song, has a tenure of 15 years and 3 days, managing assets totaling 1.397 billion CNY, with the best fund return during his tenure being 98.51% and the worst being -16.83% [3][6]. - Co-manager Cheng Fang has a tenure of 5 years and 88 days, managing assets of 538 million CNY, with the best return of 16.42% and the worst return of 1.3% during his tenure [3][6].

Core Viewpoint - Tiger Med has experienced a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the company is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - The Xiangcai Fund has a significant holding in Tiger Med, with the Xiangcai Changxing Flexible Allocation Mixed A Fund (009169) holding 20,900 shares, representing 4.73% of the fund's net value, making it the third-largest holding [2][5]. - The fund has realized a floating profit of approximately 53,100 CNY today and a total of 67,700 CNY during the three-day price increase [2][5]. - The Xiangcai Changxing Flexible Allocation Mixed A Fund was established on April 23, 2020, with a current size of 9.6681 million CNY. Year-to-date, it has incurred a loss of 5.96%, ranking 7640 out of 8898 in its category, while it has achieved a 7.24% return over the past year, ranking 5586 out of 8181 [2][5]. Fund Manager Performance - The fund managers of Xiangcai Changxing Flexible Allocation Mixed A are Che Guanglu and Bao Jiamin. Che has a tenure of 14 years and 30 days, managing assets totaling 489 million CNY, with the best fund return of 54.67% and the worst return of -40.29% during his tenure [3][6]. - Bao has a tenure of 2 years and 24 days, managing assets of 662 million CNY, with the best fund return of 60.96% and the worst return of -12.82% during her tenure [3][6].

Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over three consecutive days [1][6]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][6]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][6][7]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [7]. Shareholder Insights - Huatai-PB Fund's Huatai-PB CSI 300 ETF (510300) has entered the top ten circulating shareholders of Tiger Med, holding 8.78 million shares, which is 1.27% of the circulating shares. The estimated floating profit today is approximately 22.30 million CNY, with a total floating profit of 28.44 million CNY over the three-day increase [2][8]. - The Huatai-PB CSI 300 ETF was established on May 4, 2012, with a current scale of 422.26 billion CNY. Year-to-date, it has experienced a loss of 3.16%, ranking 3698 out of 5563 in its category, while it has gained 17.24% over the past year, ranking 2622 out of 4429 [2][8]. Fund Performance - The fund manager of Huatai-PB CSI 300 ETF is Liu Jun, who has a tenure of 16 years and 301 days, managing assets totaling 550.93 billion CNY. The best fund return during his tenure is 205.53%, while the worst is -45.64% [3][8]. - Huatai-PB Medical Health A (005805) has increased its holdings in Tiger Med by 5,950 shares, totaling 273,500 shares, which represents 5.02% of the fund's net value, making it the fourth-largest holding. The estimated floating profit today is about 694,700 CNY, with a total floating profit of 886,100 CNY over the three-day increase [4][9]. - The Huatai-PB Medical Health A fund was established on June 25, 2018, with a current scale of 251 million CNY. It has incurred a loss of 5.46% year-to-date, ranking 7497 out of 8898, while gaining 4.27% over the past year, ranking 6365 out of 8181 [4][9]. Fund Manager Insights - The fund manager of Huatai-PB Medical Health A is Zhang Hong, who has a tenure of 6 years and 145 days, managing assets totaling 2.21 billion CNY. The best fund return during his tenure is 105.24%, while the worst is -19.01% [5][10].

Core Viewpoint - Tiger Med has seen a significant stock price increase, rising 5% to 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Two funds under Yinhua Fund have significant holdings in Tiger Med, totaling 6.2985 million shares. Based on the previous closing price of 50.78 CNY, the current stock price of 53.32 CNY results in a daily floating profit of approximately 15.9982 million CNY, with a total floating profit of 20.4072 million CNY over the past three days [2][7]. - The "Innovation Drug" fund holds 6.25881 million shares, representing 0.8481% of the circulating shares and 2.86% of the fund's net value, while the "Yinhua Healthcare Mixed A" fund holds 39,700 shares, accounting for 0.0053% of the circulating shares and 5.37% of the fund's net value [3][8].